434 related articles for article (PubMed ID: 31711524)
1. Adjuvant versus early salvage radiotherapy: outcome of patients with prostate cancer treated with postoperative radiotherapy after radical prostatectomy.
Vogel MME; Kessel KA; Schiller K; Devecka M; Gschwend JE; Weichert W; Wilkens JJ; Combs SE
Radiat Oncol; 2019 Nov; 14(1):198. PubMed ID: 31711524
[TBL] [Abstract][Full Text] [Related]
2. Postoperative adjuvant and very early salvage radiotherapy after prostatectomy in high-risk prostate cancer patients can improve specific and overall survival.
Casas F; Valduvieco I; Oses G; Izquierdo L; Archila I; Costa M; Cortes KS; Barreto T; Ferrer F
Clin Transl Oncol; 2019 Mar; 21(3):355-362. PubMed ID: 30128953
[TBL] [Abstract][Full Text] [Related]
3. Salvage radiotherapy in patients with prostate cancer and biochemical relapse after radical prostatectomy : Long-term follow-up of a single-center survey.
Lohm G; Lütcke J; Jamil B; Höcht S; Neumann K; Hinkelbein W; Wiegel T; Bottke D
Strahlenther Onkol; 2014 Aug; 190(8):727-31. PubMed ID: 24577132
[TBL] [Abstract][Full Text] [Related]
4. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study.
Wiegel T; Lohm G; Bottke D; Höcht S; Miller K; Siegmann A; Schostak M; Neumann K; Hinkelbein W
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1009-16. PubMed ID: 18963539
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer.
Taylor N; Kelly JF; Kuban DA; Babaian RJ; Pisters LL; Pollack A
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):755-63. PubMed ID: 12788182
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant radiation therapy is associated with better oncological outcome compared with salvage radiation therapy in patients with pN1 prostate cancer treated with radical prostatectomy.
Tilki D; Preisser F; Tennstedt P; Tober P; Mandel P; Schlomm T; Steuber T; Huland H; Schwarz R; Petersen C; Graefen M; Ahyai S
BJU Int; 2017 May; 119(5):717-723. PubMed ID: 27743493
[TBL] [Abstract][Full Text] [Related]
7. Postoperative radiation therapy for patients at high-risk of recurrence after radical prostatectomy: does timing matter?
Hsu CC; Paciorek AT; Cooperberg MR; Roach M; Hsu IC; Carroll PR
BJU Int; 2015 Nov; 116(5):713-20. PubMed ID: 25600860
[TBL] [Abstract][Full Text] [Related]
8. A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy -- Adjuvant Versus Early Salvage (RAVES) trial.
Pearse M; Fraser-Browne C; Davis ID; Duchesne GM; Fisher R; Frydenberg M; Haworth A; Jose C; Joseph DJ; Lim TS; Matthews J; Millar J; Sidhom M; Spry NA; Tang CI; Turner S; Williams SG; Wiltshire K; Woo HH; Kneebone A
BJU Int; 2014 Mar; 113 Suppl 2():7-12. PubMed ID: 24894850
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen after salvage radiotherapy for postprostatectomy biochemical recurrence predicts long-term outcome including overall survival.
Bartkowiak D; Thamm R; Bottke D; Siegmann A; Böhmer D; Budach V; Wiegel T
Acta Oncol; 2018 Mar; 57(3):362-367. PubMed ID: 28816074
[TBL] [Abstract][Full Text] [Related]
10. The impact of salvage radiotherapy initiation at PSA ≤ 0.5 ng/ml on metastasis-free survival in patients with relapsed prostate cancer following prostatectomy.
Lee EE; Singh T; Hu C; Han M; Deville CJ; Halthore A; Greco S; Tran P; DeWeese T; Song DY
Prostate; 2023 Feb; 83(2):190-197. PubMed ID: 36316967
[TBL] [Abstract][Full Text] [Related]
11. Salvage radiotherapy in prostate cancer patients with biochemical relapse after radical prostatectomy : Prolongation of prostate-specific antigen doubling time in patients with subsequent biochemical progression.
Lohm G; Neumann K; Budach V; Wiegel T; Hoecht S; Gollrad J
Strahlenther Onkol; 2018 Apr; 194(4):325-332. PubMed ID: 29255924
[TBL] [Abstract][Full Text] [Related]
12. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
[TBL] [Abstract][Full Text] [Related]
13. Salvage radiotherapy for biochemical recurrence after radical prostatectomy: does the outcome depend on the prostate cancer characteristics?
Viani GA; Hamamura AC; Correa AC; de Arruda FT
Int Braz J Urol; 2019; 45(2):237-245. PubMed ID: 30676298
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy after radical prostatectomy for prostate cancer: clinical outcomes and factors influencing biochemical recurrence.
Fukuda I; Aoki M; Kimura T; Ikeda K
Ir J Med Sci; 2023 Dec; 192(6):2663-2671. PubMed ID: 37097540
[TBL] [Abstract][Full Text] [Related]
15. Variation in the use of postoperative radiotherapy among high-risk patients following radical prostatectomy.
Morgan TM; Hawken SR; Ghani KR; Miller DC; Feng FY; Linsell SM; Salisz JA; Gao Y; Montie JE; Cher ML
Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):216-21. PubMed ID: 26951715
[TBL] [Abstract][Full Text] [Related]
16. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant versus salvage radiotherapy in prostate cancer: multi-institutional retrospective analysis of the Spanish RECAP database.
Hervás A; Gómez-Caamaño A; Casaña M; Gómez-Iturriaga A; Pastor J; Jove J; Mengual JL; Gónzalez-San Segundo C; Muñoz J
Clin Transl Oncol; 2018 Feb; 20(2):193-200. PubMed ID: 28667448
[TBL] [Abstract][Full Text] [Related]
18. Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series.
Fossati N; Karnes RJ; Boorjian SA; Moschini M; Morlacco A; Bossi A; Seisen T; Cozzarini C; Fiorino C; Noris Chiorda B; Gandaglia G; Dell'Oglio P; Joniau S; Tosco L; Shariat S; Goldner G; Hinkelbein W; Bartkowiak D; Haustermans K; Tombal B; Montorsi F; Van Poppel H; Wiegel T; Briganti A
Eur Urol; 2017 Jun; 71(6):886-893. PubMed ID: 27484843
[TBL] [Abstract][Full Text] [Related]
19. Impact of pathological tumor stage for salvage radiotherapy after radical prostatectomy in patients with prostate-specific antigen < 1.0 ng/ml.
Umezawa R; Ariga H; Ogawa Y; Jingu K; Matsushita H; Takeda K; Fujimoto K; Sakayauchi T; Sugawara T; Kubozono M; Narazaki K; Shimizu E; Takai Y; Yamada S
Radiat Oncol; 2011 Nov; 6():150. PubMed ID: 22053922
[TBL] [Abstract][Full Text] [Related]
20. A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer.
Trabulsi EJ; Valicenti RK; Hanlon AL; Pisansky TM; Sandler HM; Kuban DA; Catton CN; Michalski JM; Zelefsky MJ; Kupelian PA; Lin DW; Anscher MS; Slawin KM; Roehrborn CG; Forman JD; Liauw SL; Kestin LL; DeWeese TL; Scardino PT; Stephenson AJ; Pollack A
Urology; 2008 Dec; 72(6):1298-302; discussion 1302-4. PubMed ID: 18672274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
